These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


Pubmed for Handhelds

PUBMED FOR HANDHELDS

Journal Abstract Search

321 related items for PubMed ID: 7037174

  • 21. New drugs in ovarian cancer and malignant melanoma: in vitro phase II screening with the human tumor stem cell assay.
    Salmon SE, Meyskens FL, Alberts DS, Soehnlen B, Young L.
    Cancer Treat Rep; 1981; 65(1-2):1-12. PubMed ID: 7226159
    [Abstract] [Full Text] [Related]

  • 22.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 23. Phase I study of methanesulfonamide, N-[4-(9-acridinylamino)-3-methoxyphenyl]-(m-AMSA) using a single-dose schedule.
    Von Hoff DD, Howser K, Gormley P, Bender RA, Glaubiger D, Levine AS, Young RC.
    Cancer Treat Rep; 1978 Oct; 62(10):1421-6. PubMed ID: 361222
    [Abstract] [Full Text] [Related]

  • 24.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 25.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 26. Phase I clinical trial of pyrazoloacridine NSC366140 (PD115934).
    LoRusso P, Foster BJ, Poplin E, McCormick J, Kraut M, Flaherty L, Heilbrun LK, Valdivieso M, Baker L.
    Clin Cancer Res; 1995 Dec; 1(12):1487-93. PubMed ID: 9815948
    [Abstract] [Full Text] [Related]

  • 27. Simultaneous paclitaxel and radiotherapy: initial clinical experience in lung cancer and other malignancies.
    Vogt HG, Martin T, Kolotas C, Schneider L, Strassmann G, Zamboglou N.
    Semin Oncol; 1997 Aug; 24(4 Suppl 12):S12-101-S12-105. PubMed ID: 9331131
    [Abstract] [Full Text] [Related]

  • 28. Aggressive simultaneous radiochemotherapy with cisplatin and paclitaxel in combination with accelerated hyperfractionated radiotherapy in locally advanced head and neck tumors. Results of a phase I-II trial.
    Kuhnt T, Becker A, Pigorsch S, Pelz T, Bloching M, Passmann M, Lotterer E, Hänsgen G, Dunst J.
    Strahlenther Onkol; 2003 Oct; 179(10):673-81. PubMed ID: 14566475
    [Abstract] [Full Text] [Related]

  • 29. Phase I study of a five-day dose schedule of 4-Ipomeanol in patients with non-small cell lung cancer.
    Kasturi VK, Dearing MP, Piscitelli SC, Russell EK, Sladek GG, O'Neil K, Turner GA, Morton TL, Christian MC, Johnson BE, Kelley MJ.
    Clin Cancer Res; 1998 Sep; 4(9):2095-102. PubMed ID: 9748125
    [Abstract] [Full Text] [Related]

  • 30. Phase I and clinical pharmacological evaluation of 4'-deoxydoxorubicin in patients with advanced cancer.
    Stanton GF, Raymond V, Wittes RE, Schulman P, Budman D, Baratz R, Williams L, Petroni GR, Geller NL, Hancock C.
    Cancer Res; 1985 Apr; 45(4):1862-8. PubMed ID: 3978646
    [Abstract] [Full Text] [Related]

  • 31. Activation of tumor-cytostatic macrophages with the antitumor agent 9,10-anthracenedicarboxaldehyde bis[(4,5-dihydro-1H-imidazole-2-yl)hydrazone] dihydrochloride (bisantrene).
    Wang BS, Lumanglas AL, Ruszala-Mallon VM, Durr FE.
    Cancer Res; 1984 Jun; 44(6):2363-7. PubMed ID: 6426780
    [Abstract] [Full Text] [Related]

  • 32. Phase I clinical and pharmacokinetic study of kahalalide F administered weekly as a 1-hour infusion to patients with advanced solid tumors.
    Pardo B, Paz-Ares L, Tabernero J, Ciruelos E, García M, Salazar R, López A, Blanco M, Nieto A, Jimeno J, Izquierdo MA, Trigo JM.
    Clin Cancer Res; 2008 Feb 15; 14(4):1116-23. PubMed ID: 18281545
    [Abstract] [Full Text] [Related]

  • 33. Phase I and pharmacological study of single paclitaxel administered weekly for heavily pre-treated patients with epithelial ovarian cancer.
    Takano M, Kikuchi Y, Kita T, Suzuki M, Ohwada M, Yamamoto T, Yamamoto K, Inoue H, Shimizu K.
    Anticancer Res; 2002 Feb 15; 22(3):1833-8. PubMed ID: 12168878
    [Abstract] [Full Text] [Related]

  • 34. Phase I and pharmacokinetic study of E7070, a chloroindolyl-sulfonamide anticancer agent, administered on a weekly schedule to patients with solid tumors.
    Dittrich C, Dumez H, Calvert H, Hanauske A, Faber M, Wanders J, Yule M, Ravic M, Fumoleau P.
    Clin Cancer Res; 2003 Nov 01; 9(14):5195-204. PubMed ID: 14613999
    [Abstract] [Full Text] [Related]

  • 35.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 36. Phase II evaluation of amsacrine (m-AMSA) in solid tumors, myeloma, and lymphoma: a University of Arizona and Southwest Oncology Group Study.
    Ahmann FR, Meyskens FL, Jones SE, Bukowski RM, Saiers JH, Ryan DH, Costanzi J, Vaughn CB, Coltman CA.
    Cancer Treat Rep; 1983 Nov 01; 67(7-8):697-700. PubMed ID: 6688199
    [Abstract] [Full Text] [Related]

  • 37. Phase I study of a 5-day schedule of mitoxantrone (dihydroxyanthracenedione).
    Wynert WR, Harvey HA, Lipton A, Schweitzer J, White DS.
    Cancer Treat Rep; 1982 Jun 01; 66(6):1303-6. PubMed ID: 7083234
    [Abstract] [Full Text] [Related]

  • 38.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 39.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 40.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

    Page: [Previous] [Next] [New Search]
    of 17.